Cancer Clinical Trial
Official title:
A Double-Blind, Placebo-Comparison Study to Evaluate the Efficacy and Safety of ACTIQ® (Oral Transmucosal Fentanyl Citrate [OTFC®]) Treatment for Opioid-Tolerant Children and Adolescents With Breakthrough Pain
The primary objective of the study is to evaluate the efficacy of ACTIQ treatment for the management of breakthrough pain (BTP) compared to placebo treatment in children with cancer and non-cancer pain who are receiving around-the-clock (ATC) opioid therapy and who require additional therapy for BTP episodes. This will be determined by the analysis of the pain intensity (PI), measured by the Faces Pain Scale-Revised (FPS-R) administered 15 minutes after the start of each unit of study drug with an optimal ACTIQ dosage.
The primary objective of the study is to evaluate the efficacy of ACTIQ treatment for the
management of breakthrough pain (BTP) compared to placebo treatment in children with pain
who are receiving around-the-clock (ATC) opioid therapy and who require additional therapy
for BTP episodes. This will be determined by the analysis of the pain intensity (PI),
measured by the Faces Pain Scale-Revised (FPS-R) administered 15 minutes after the start of
each unit of study drug with an optimal ACTIQ dosage.
The secondary objectives are:
- to evaluate the characteristics of BTP in children with pain, including their response
to treatment
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children with regard to time to adequate analgesia by utilizing a stop watch to measure
the time for each unit of study drug in the double blind phase
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children by assessing the occurrence of inadequate analgesia as assessed by the use of
rescue medication
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children by assessing the numbers of patients who withdraw from the study because of
inadequate analgesia
- to evaluate the efficacy of ACTIQ treatment compared to placebo treatment for these
children by assessing the duration of analgesic effect by using the FPS-R administered
at approximately 30, 45, and 60 minutes after the start of each unit of study drug
after an optimal dosage is obtained
- to determine the distribution of optimal doses of ACTIQ treatment for these children by
age group (3 to under 6 years, 6 to under 11 years, and 11 to under 16 years)
- to establish a safe and effective titration scheme for ACTIQ in these children during
the open label phase
- to evaluate the safety of ACTIQ treatment for these children through the assessment of
adverse events, clinical laboratory assessments (serum chemistry and hematology), vital
sign measurements (including blood pressure, heart rate, and respiration rate),
hemoglobin-oxygen saturation level (SpO2, measured via pulse oximetry),
electrocardiograms (ECGs), physical examinations, and level of sedation (measured by
the University of Michigan Sedation Scale [UMSS])
- to characterize the pharmacokinetics profile of ACTIQ (fentanyl citrate) in these
children
- to investigate the exposure and efficacy relationship between plasma concentration of
fentanyl and clinical measures of analgesia
;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|
||
| Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|